UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 371

Sortiert nach

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Alimentary pharmacology & therapeutics, 2011-08, Vol.34 (3), p.274-285

2011

Link zum Volltext

Verfügbarkeit prüfen

Associations of chronic hepatitis C with metabolic and cardiac outcomes

Alimentary pharmacology & therapeutics, 2013-03, Vol.37 (6), p.647-652

2013

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.497-520

2015

Link zum Volltext

Verfügbarkeit prüfen

Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Alimentary pharmacology & therapeutics, 2008-07, Vol.28 (1), p.2-12

YOUNOSSI, Z. M.

2008

Link zum Volltext

Verfügbarkeit prüfen

Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity

Gastroenterology (New York, N.Y. 1943), 1999-06, Vol.116 (6), p.1413-1419

1999

Link zum Volltext

Verfügbarkeit prüfen

Adipokines and cytokines in non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2008-03, Vol.27 (5), p.412-421

2008

Link zum Volltext

Verfügbarkeit prüfen

Caffeine is protective in patients with non-alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2012-01, Vol.35 (1), p.76-82

2012

Link zum Volltext

Verfügbarkeit prüfen

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study

Alimentary pharmacology & therapeutics, 2012-10, Vol.36 (8), p.772-781

2012

Link zum Volltext

Verfügbarkeit prüfen

Editorial: direct‐acting antivirals significantly improve quality of life in patients with hepatitis C virus infection—Author's reply

Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (4), p.537-538

Younossi, Z. M.

2018

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2011-04, Vol.33 (7), p.801-814

2011

Link zum Volltext

Verfügbarkeit prüfen

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.544-563

2015

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.3-14

2014

Link zum Volltext

Verfügbarkeit prüfen

The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.686-694

2014

Link zum Volltext

Verfügbarkeit prüfen

A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection

Journal of viral hepatitis, 2015-11, Vol.22 (11), p.897-905

2015

Link zum Volltext

Verfügbarkeit prüfen

The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.286-295

2015

Link zum Volltext

Verfügbarkeit prüfen

Differential expression of miRNAs in the visceral adipose tissue of patients with non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (3), p.487-497

2010

Link zum Volltext

Verfügbarkeit prüfen

The impact of hepatitis C burden: an evidence‐based approach

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.518-531

2014

Link zum Volltext

Verfügbarkeit prüfen

Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

Gut, 1999-08, Vol.45 (2), p.295-300

1999

Link zum Volltext

Verfügbarkeit prüfen

Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (5), p.680-688

2018

Link zum Volltext

Verfügbarkeit prüfen

Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.703-709

2013

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.259-267

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

Alimentary pharmacology & therapeutics, 2011-10, Vol.34 (8), p.853-861

2011

Link zum Volltext

Verfügbarkeit prüfen

Predictors of health‐related quality of life in patients with chronic liver disease

Alimentary pharmacology & therapeutics, 2009-09, Vol.30 (5), p.469-476

2009

Link zum Volltext

Verfügbarkeit prüfen

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan

Journal of viral hepatitis, 2018-08, Vol.25 (8), p.945-951

2018

Link zum Volltext

Verfügbarkeit prüfen

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.676-685

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 371

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(364)
Mit Volltextzugriff
(344)

Publikationsform

Sprache

Englisch
(370)
Japanisch
(33)
Deutsch
(3)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(177)
Science & Technology
(177)
Humans
(174)
Gastroenterology & Hepatology
(136)
Female
(114)
Male
(114)
Middle Aged
(102)
Adult
(81)
Biological And Medical Sciences
(74)
Medical Sciences
(73)
Gastroenterology And Hepatology
(70)
Infectious Diseases
(49)
Aged
(44)
Hepatitis C, Chronic - Drug Therapy
(44)
Pharmacology & Pharmacy
(43)
Antiviral Agents - Therapeutic Use
(39)
Quality Of Life
(36)
Drug Therapy, Combination
(34)
Gastroenterology. Liver. Pancreas. Abdomen
(33)
Hepatitis C
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Associations of chronic hepatitis C with metabolic and cardiac outcomes

Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens

Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity

Adipokines and cytokines in non‐alcoholic fatty liver disease

Caffeine is protective in patients with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study

Editorial: direct‐acting antivirals significantly improve quality of life in patients with hepatitis C virus infection—Author's reply

Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non‐alcoholic fatty liver disease

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets

The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US

A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection

The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life

Differential expression of miRNAs in the visceral adipose tissue of patients with non‐alcoholic fatty liver disease

The impact of hepatitis C burden: an evidence‐based approach

Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality

Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

Predictors of health‐related quality of life in patients with chronic liver disease

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Suchergebnisse filtern